GlassScriptPhysician profile
Rachel Call
NPI 1265035166
$1,879.23
in general payments reported to CMS, 2019-2025
20 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Consulting Fee: $26.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.36 |
| Consulting Fee | $26.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $302.11 | 2025 | Airsupra, Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $189.62 | 2025 | |
| Csl Behring | $182.64 | 2025 | Andembry, Hizentra, Haegarda |
| Genzyme Corporation | $169.80 | 2025 | |
| Pharming Healthcare, INC. | $146.59 | 2025 | Ruconest |
| Organon LLC | $139.63 | 2022 | |
| Glaxosmithkline, LLC. | $109.37 | 2025 | Nucala, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $86.53 | 2025 | Glassia, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $78.56 | 2025 | Dupixent |
| Blueprint Medicines Corporation | $73.28 | 2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $68.92 | 2025 | Neffy |
| Incyte Corporation | $53.10 | 2025 | Opzelura |
| Genentech USA, INC. | $46.16 | 2025 | Xolair |
| Amgen INC. | $41.02 | 2025 | Tezspire |
| Tersera Therapeutics LLC | $39.18 | 2025 | Quzyttir |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $36.91 | 2025 | Anzupgo |
| Biocryst US Sales Co., LLC | $32.88 | 2025 | Orladeyo |
| Lilly USA, LLC | $31.59 | 2025 | Ebglyss |
| Adma Biomanufacturing LLC | $26.24 | 2025 | |
| Octapharma USA, INC. | $25.10 | 2025 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.